Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
| ▸ | NFE2 | Q16621 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260929 | 0.76 | RXFP1 (0.52) | MEN1KMT2AGAA | |
| SCHEMBL12216015 | 0.69 | CDK8 (0.69) | HPGDJAK2CDK8MAPK14CCNC | |
| SCHEMBL1013690 | 0.68 | MAPK13 (0.59) | JAK2RECQLCDK8MAPK14GAA | |
| SCHEMBL4226618 | 0.68 | CDK8 (0.63) | NTRK1NTRK2HPGDJAK2CDK8 | |
| SCHEMBL1284027 | 0.68 | JAK2 (0.81) | JAK2MEN1KMT2ACDK8MAPK14 | |
| SCHEMBL20627057 | 0.67 | NTRK1 (0.53) | NTRK1NTRK2HPGDJAK2CDK8 | |
| SCHEMBL3920266 | 0.66 | KMT2A (0.57) | HPGDMEN1KMT2A | |
| SCHEMBL1600309 | 0.66 | CDK8 (0.82) | JAK2CDK8MAPK14GAACCNC | |
| SCHEMBL13852780 | 0.66 | MAPK14 (0.82) | MAPK14 | |
| SCHEMBL4264820 | 0.66 | TSHR (0.58) | HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | NTRK1 3857/4885NTRK2 2513/4885HPGD 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.